Uncategorized

Lilly wants to bridge cancer care gap with $300M ADC biotech buy

Published

on

Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version